Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

A Comparative Study on Trends and Efficacy of Erythropoietin Stimulating Agents in Patient Receiving Peritoneal Dialysis

복막투석 환자의 빈혈 관리에 있어 에리스로포이에틴 자극제의 사용현황 및 비교평가

  • Lim, Soo Yeon (Graduate School of Clinical Health Sciences, Ewha Womans University) ;
  • Jin, Hye Kyung (College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University) ;
  • Kim, Sun Ah (Ewha Womans University Medical Center) ;
  • Lee, Eun Kyung (Ewha Womans University Medical Center) ;
  • Rhie, Sandy (Graduate School of Clinical Health Sciences, Ewha Womans University)
  • 임수연 (이화여자대학교 임상보건과학대학원) ;
  • 진혜경 (이화여자대학교 약학대학) ;
  • 김선아 (이화여자대학교부속 목동병원 약제과) ;
  • 이은경 (이화여자대학교부속 목동병원 약제과) ;
  • 이정연 (이화여자대학교 임상보건과학대학원)
  • Received : 2014.05.02
  • Accepted : 2014.08.25
  • Published : 2014.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: This was to evaluate the current usage of three erythropoietin stimulating agents (ESA) and their efficacy for management of anemia in peritoneal dialysis (PD) patients with chronic kidney disease. Methods: It was a retrospective comparative study through review of electronic medical records of chronic kidney disease patients undergoing PD at a tertiary teaching hospital from January 1998 to June 2013. Results: Average administration frequency was 1.66 times/week in EPO group, 0.75 times/week in DA group, and 0.19 times/week in MPG-EPO group. At the first 4 weeks, there were significant differences in mean hemoglobin levels between EPO and DA groups ($9.25{\pm}1.28g/dL$, $10.02{\pm}0.95g/dL$ each, p = 0.018) and also in hemoglobin response rates (10.0%, 45.2% each, p = 0.008), but since after 4 week, there had been no significant differences. There also showed no significant differences in achievement of hemoglobin target between the two groups. When converted to MPG-EPO in EPO/DA groups, there showed a slight increase in hemoglobin levels of both groups. MPG-EPO was the highest compared with two other drugs by the average cost based on the average weekly dose. Conclusion: EPO, DA, and MPG-EPO showed similar effects in treatment of anemia of PD patients based on hemoglobin target range (11.0~12.0 g/dL) which NFK-K/DOQI guidelines suggest. Though the average cost of MPG-EPO was higher than the other two drugs, the number of PD patients using MPG-EPO has increased and it is thought that long half-life and low administration frequency of MPG-EPO have improved the compliance of PD patients who have to self-administrate.

Keywords

References

  1. Jin DC. Current status of dialysis therapy for ESRD patients in KOREA. J Korean Med Assoc 2013;56(7):562- 8. https://doi.org/10.5124/jkma.2013.56.7.562
  2. Yang CW. Current status and future in patients with end stage renal disease in KOREA. J Korean Med Assoc 2013; 56(7):560-1. https://doi.org/10.5124/jkma.2013.56.7.560
  3. Li S, Foley RN, Collins AJ. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 2004;65(5):1864-9. https://doi.org/10.1111/j.1523-1755.2004.00584.x
  4. Ohashi N, Sakao Y, Yasuda H, et al. Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease. Int J Nephrol Renovasc Dis 2012;5:53-60.
  5. Ahn SC, Choi SO, Shin SJ, et al. Anemia in patients with chronic renal failure on hemodialysis. Kidney Res Clin Pract 1994;13(4):769-75.
  6. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(5 suppl 3):S11-145. https://doi.org/10.1053/j.ajkd.2006.03.010
  7. Shimosaka A. Pharmacokinetics and Application of Erythropoietin Therapy: Overview of Epoetin Alfa Studies in Japan. Ann N Y Acad Sci 1994;718:111-22.
  8. Horl WH. Differentiating factors between erythropoiesis stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs 2013;73(2):117-30. https://doi.org/10.1007/s40265-012-0002-2
  9. Padhi D, Ni L, Cooke B, et al. An extended terminal halflife for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 2006;45(5):503-10. https://doi.org/10.2165/00003088-200645050-00005
  10. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10(11):2392-5.
  11. Locatelli F, Reigner B. C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opin Investig Drugs 2007;16(10): 1649-61. https://doi.org/10.1517/13543784.16.10.1649
  12. Curran MP, McCormack PL. Methoxy polyethylene glycolepoetin beta: A review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008;68(8):1139-56. https://doi.org/10.2165/00003495-200868080-00009
  13. Dougherty FC, Reigner B, Jordan P, et al. Continuous erythropoiesis receptor activator (CERA) provides dosedependent erythropoietic activity with a prolonged half-life in healthy volunteers. Ann Oncol 2004; 15(suppl 3): iii157 (Abstr 2943).
  14. Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006;1:1211-5. https://doi.org/10.2215/CJN.00730306
  15. Klinger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 2013.
  16. Wazny LD, Stojimirovic BB, Heidenheim P, et al. Factors influencing erythropoietin compliance in peritoneal dialysis patients. Am J Kidney Dis 2002;40(3):623-8. https://doi.org/10.1053/ajkd.2002.34925
  17. Lee JY, Byun SW, Yeo YS, et al. Comparison of erythropoietic effect between epoetin-${\alpha}$ and darbepoetin-a in hemodialysis patients: A randomized crossover study. Kidney Res Clin Pract 2009;28(5):450-5.
  18. Yoo SH, Kang JM, Kang GW, et al. Phase III clinical study of recombinant human erythropoietin (Eporon(R)) on anemia of chronic renal failure. Kidney Res Clin Pract 2000;19(6):1053- 62.
  19. Product Information: MIRCERA(R) injection, methoxy polyethylene glycol-eopetin beta injection. Hoffmann-La Roche,Inc, Nutley, NJ, 2007.
  20. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40(1):110-8. https://doi.org/10.1053/ajkd.2002.33919
  21. Vanrenterghem Y, Barany P, Mann JF, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002;62(6):2167-75. https://doi.org/10.1046/j.1523-1755.2002.00657.x
  22. Shin SH, Lee YS. Determinants of erythropoietin hyporesponsiveness in management of anemia in hemodialysis patients. Kor J Clin Pharm 2011;21(2):122-30.
  23. Klinger M, Arias M, Vargemezis V, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kideny Dis 2007;50(6):989-1000. https://doi.org/10.1053/j.ajkd.2007.08.013
  24. Carrera F, Lok CE, de Francisco A, et al. Maintenance treatment of renal anemia in hemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 2010;25(12):4009-17. https://doi.org/10.1093/ndt/gfq305
  25. Park SK, Hwang KS, Park JS, et al. Hemoglobin variability associated with different erythropoiesis stimulating agents in hemodialysis patients. Kidney Res Clin Pract 2011;30(1):41-7.
  26. Sikand H, Decter A, Greco T, et al. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen. Ann Pharmacother 2008;42(1):16-23. https://doi.org/10.1345/aph.1K061
  27. Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. Eur J Clin Pharmacol 1996;50(3):171-7. https://doi.org/10.1007/s002280050088